Please contact our sales team for your Consulting and Customization queries/concerns at [email protected].
Familial Amyloid Neuropathies Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Familial Amyloid Neuropathies - Drugs In Development, 2022, provides an overview of the Familial Amyloid Neuropathies (Metabolic Disorders) pipeline landscape.
Familial amyloid neuropathy is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues. Symptoms include numbness, tingling, pins and needles in the feet and hands, weakness and pain in the arms and legs, loss of sensation, urinary retention, reduced sweating, ankle swelling, fatigue, nausea, weight loss, dizziness and fainting. Supportive treatment includes diuretics, calcium channel blockers, beta blockers, angiotensin receptor blockers and angiotensin converting enzyme (ACE) inhibitors.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Familial Amyloid Neuropathies - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Familial Amyloid Neuropathies (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Familial Amyloid Neuropathies (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Familial Amyloid Neuropathies and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 3, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.
Familial Amyloid Neuropathies (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Familial Amyloid Neuropathies (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Familial Amyloid Neuropathies (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Familial Amyloid Neuropathies (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Familial Amyloid Neuropathies (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Familial Amyloid Neuropathies (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Familial Amyloid Neuropathies (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Familial Amyloid Neuropathies (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Familial Amyloid Neuropathies - Overview
Familial Amyloid Neuropathies - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Familial Amyloid Neuropathies - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Familial Amyloid Neuropathies - Companies Involved in Therapeutics Development
ADRx Inc
Akcea Therapeutics Inc
Alnylam Pharmaceuticals Inc
BSIM Therapeutics SA
Corino Therapeutics Inc
Novo Nordisk AS
Proclara Biosciences Inc
Regeneron Pharmaceuticals Inc
Familial Amyloid Neuropathies - Drug Profiles
Antibody to Inhibit TTR for Familial Transthyretin Amyloidosis - Drug Profile
Product Description
Mechanism Of Action
CLR-01 - Drug Profile
Product Description
Mechanism Of Action
doxycycline hyclate - Drug Profile
Product Description
Mechanism Of Action
eplontersen sodium - Drug Profile
Product Description
Mechanism Of Action
NNC-6019 - Drug Profile
Product Description
Mechanism Of Action
NPT-189 - Drug Profile
Product Description
Mechanism Of Action
NTLA-2001 - Drug Profile
Product Description
Mechanism Of Action
patisiran - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy - Drug Profile
Product Description
Mechanism Of Action
tolcapone - Drug Profile
Product Description
Mechanism Of Action
vutrisiran - Drug Profile
Product Description
Mechanism Of Action
Familial Amyloid Neuropathies - Dormant Projects
Familial Amyloid Neuropathies - Discontinued Products
Familial Amyloid Neuropathies - Product Development Milestones
Featured News & Press Releases
Sep 07, 2022: Ionis presents positive results from phase 3 NEURO-TTRansform study at International Symposium on Amyloidosis
Jun 22, 2022: AstraZeneca-Ionis eplontersen meets endpoints in Phase III ATTRv-PN trial
Oct 27, 2021: Alnylam reports positive topline 18-month results from HELIOS-A phase 3 study of Vutrisiran in patients with hATTR amyloidosis with polyneuropathy
Jun 24, 2021: Alnylam announces U.S. Food and Drug Administration acceptance of new drug application for investigational Vutrisiran for the treatment of the polyneuropathy of hereditary ATTR amyloidosis
Nov 13, 2017: European Medicines Agency (EMA) Grants Alnylam Accelerated Assessment of Patisiran for Patients with Hereditary ATTR (hATTR) Amyloidosis
Nov 02, 2017: Sanofi and Alnylam Present Positive Complete Results from APOLLO Phase 3 study of Investigational Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
Sep 20, 2017: Arbutus LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program
Sep 20, 2017: Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
Apr 26, 2017: Alnylam Reports Final 24-Month Results from Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
Oct 10, 2016: Data Monitoring Committee Recommends Continuation of APOLLO Phase 3 Clinical Trial of Patisiran for Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN)
Aug 16, 2016: BSIM Therapeutics was awarded research and development contract fund
Jul 01, 2016: Alnylam Reports New Results on patisiran at the XV International Symposium on Amyloidosis
Jun 27, 2016: Alnylam to Report New Patisiran Results at the XV International Symposium on Amyloidosis
Apr 20, 2016: Alnylam Reports Complete 18-Month Data from Ongoing Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN)
Feb 01, 2016: Alnylam Completes Enrollment in APOLLO Phase 3 Study with Patisiran, an Investigational RNAi Therapeutic for Patients with Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Familial Amyloid Neuropathies, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Familial Amyloid Neuropathies - Pipeline by ADRx Inc, 2022
Familial Amyloid Neuropathies - Pipeline by Akcea Therapeutics Inc, 2022
Familial Amyloid Neuropathies - Pipeline by Alnylam Pharmaceuticals Inc, 2022
Familial Amyloid Neuropathies - Pipeline by BSIM Therapeutics SA, 2022
Familial Amyloid Neuropathies - Pipeline by Corino Therapeutics Inc, 2022
Familial Amyloid Neuropathies - Pipeline by Novo Nordisk AS, 2022
Familial Amyloid Neuropathies - Pipeline by Proclara Biosciences Inc, 2022
Familial Amyloid Neuropathies - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Familial Amyloid Neuropathies - Dormant Projects, 2022
Familial Amyloid Neuropathies - Discontinued Products, 2022
List of Figures
Number of Products under Development for Familial Amyloid Neuropathies, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
|
Familial Amyloid Neuropathies (Metabolic Disorder) - Drugs in Development, 2021
Familial Amyloid Neuropathies (Metabolic Disorder) - Drugs in Development, 2021 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Familial Amyloid Neuropathies Drugs In Development... |
